Pregnancy and Infant Outcomes in Anifrolumab Exposed Pregnancies Using PRegnancy Outcomes Intensive Monitoring (PRIM) Data: The Anifrolumab PRIM Program
Latest Information Update: 04 Feb 2025
Price :
$35 *
At a glance
- Drugs Anifrolumab (Primary)
- Indications Cutaneous lupus erythematosus; Lupus nephritis; Myositis; Scleroderma; Sjogren's syndrome; Systemic lupus erythematosus
- Focus Adverse reactions
- Sponsors AstraZeneca
- 04 Feb 2025 New trial record